NCT05667415

Treatment of Advance Gastric Cancer With Disulfiram

Not yet recruiting NA Last updated 28 December 2022

What this trial tests

NA trial testing disulfiram and cisplatin in Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram in 40 participants. Not yet recruiting.

Timeline

1 June 2023

Primary endpoint
31 December 2025

30 June 2026

Quick facts

Lead sponsor	First People's Hospital of Hangzhou
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 June 2023
Primary completion	31 December 2025
Estimated completion	30 June 2026
Sites	1 location across China

Drugs / interventions tested

• disulfiram and cisplatin — full drug profile →
• cisplatin (cisplatin) — full drug profile →

Conditions studied

• Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram — all drugs for Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram →

Sponsor

First People's Hospital of Hangzhou

Who can join

18 and older, any sex, with Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chemotherapy is generally needed for advanced gastric cancer, and cisplatin is the main chemotherapy drug. However, there are many adverse reactions, including bone marrow suppression, gastrointestinal reactions, renal toxicity and neurotoxicity. These adverse reactions can affect the comfort and compliance of patients during treatment. At present, it is necessary to reduce adverse reactions of cisplatin and increase the chemotherapy sensitivity of gastric cancer to cisplatin. Recent studies have found that disulfiram has a potential anti-tumor effect. The disulfiram has shown significant in vivo and in vitro anti-tumor activity in preclinical studies, and has become a potential candidate drug for tumor treatment as an adjuvant in various clinical trials. In this clinical study, cisplatin combined with disulfiram is mainly used to treat advanced gastric cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer.
   Guo Z, Chen D, Yao L, Sun Y, et al · · 2025 · cited 63× · PMID 40341098 · DOI 10.1038/s41392-025-02192-0
2. Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems.
   Kang X, Jadhav S, Annaji M, Huang CH, et al · · 2023 · cited 35× · PMID 37376016 · DOI 10.3390/pharmaceutics15061567
3. Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials.
   Wang J, Li J, Liu J, Chan KY, et al · · 2024 · cited 33× · PMID 38339263 · DOI 10.3390/cancers16030512
4. Copper in colorectal cancer: From copper-related mechanisms to clinical cancer therapies.
   Wang Y, Pei P, Yang K, Guo L, et al · · 2024 · cited 32× · PMID 38804588 · DOI 10.1002/ctm2.1724
5. Copper homeostasis and cuproptosis in tumor pathogenesis and therapeutic strategies.
   Bian C, Zheng Z, Su J, Chang S, et al · · 2023 · cited 29× · PMID 37767404 · DOI 10.3389/fphar.2023.1271613
6. Cuproptosis, the novel type of oxidation-induced cell death in thoracic cancers: can it enhance the success of immunotherapy?
   Zhao R, Sukocheva O, Tse E, Neganova M, et al · · 2024 · cited 24× · PMID 39068453 · DOI 10.1186/s12964-024-01743-2
7. Copper in melanoma: At the crossroad of protumorigenic and anticancer roles.
   Chrzan N, Hartman ML. · · 2025 · cited 18× · PMID 39970778 · DOI 10.1016/j.redox.2025.103552
8. Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies.
   Huang D, Yao Y, Lou Y, Kou L, et al · · 2024 · cited 5× · PMID 39678262 · DOI 10.1016/j.ijpx.2024.100307